Literature DB >> 137718

The primary inhibitor of plasmin in human plasma.

S Müllertz, I Clemmensen.   

Abstract

A complex between plasmin and an inhibitor was isolated by affinity chromatography from urokinase-activated human plasma. The complex did not react with antibodies against any of the known proteinase inhibitors in plasma. A rabbit antiserum against the complex was produced. It contained antibodies agianst plasminogen+plasmin and an alpha2 protein. By crossed immunoelectrophoresis the alpha2 protein was shown to form a complex with plasmin, when generated by urokinase in plasma, and with purified plasmin. The alpha2 protein was eluted by Sephadex G-200 gel filtration with KD approx. 0.35, different from the other inhibitors of plasmin in plasma, and corresponding to an apparent relative molecular mass (Mr) of about 75000. By sodium dodecyl sulphate/polyacrylamide-gel electrophoresis, the Mr of the complex was found to be approx. 130000. After reduction of the complex two main bands of protein were observed, with Mr, about 72000 and 66000, probably representing an acyl-enzyme complex of plasmin-light chain and inhibitor-heavy chain, and a plasmin-heavy chain. A weak band with Mr 9000 was possibly an inhibitor-light chain. The inhibitor was partially purified and used to titrate purified plasmin of known active-site concentration. The inhibitor bound plasmin rapidly and strongly. Assuming an equimolar combining ratio, the concentration of active inhibitor in normal human plasma was estimated to be 1.1 mumol/1. A fraction about 0.3 of the antigenic inhibitor protein appeared to be functionally inactive. In plasma, plasmin is primarily bound to the inhibitor. Only after its saturation does lysis of fibrinogen and fibrin occur and a complex between plasmin and alpha2 macroglobulin appear.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 137718      PMCID: PMC1164152          DOI: 10.1042/bj1590545

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  33 in total

1.  Immunochemical distinction between antiplasmin and alpha-antitrypsin.

Authors:  D Collen; M Verstraete
Journal:  Thromb Res       Date:  1975-07       Impact factor: 3.944

2.  The action of antithrombin III on plasmin and activators of plasminogen.

Authors:  G P Crawford; D Ogston
Journal:  Biochim Biophys Acta       Date:  1975-05-23

Review 3.  MECHANISM OF ACTION OF PROTEOLYTIC ENZYMES.

Authors:  M L BENDER; J KEZDY
Journal:  Annu Rev Biochem       Date:  1965       Impact factor: 23.643

4.  Competition among trypsin inhibitors.

Authors:  N M GREEN
Journal:  J Biol Chem       Date:  1953-12       Impact factor: 5.157

5.  The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin.

Authors:  K C Robbins; L Summaria; B Hsieh; R J Shah
Journal:  J Biol Chem       Date:  1967-05-25       Impact factor: 5.157

6.  The plasmin inhibitor of human plasma. IV. Its action on plasmin, trypsin, chymotrypsin, and thrombin.

Authors:  A Rimon; Y Shamash; B Shapiro
Journal:  J Biol Chem       Date:  1966-11-10       Impact factor: 5.157

7.  Molecular forms of plasmin and protease inhibitors in human fibrinolytic post-mortem plasma.

Authors:  S Müllertz
Journal:  Scand J Clin Lab Invest       Date:  1972-12       Impact factor: 1.713

8.  Electroimmuno assay.

Authors:  C B Laurell
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

9.  Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.

Authors:  P C Harpel; N R Cooper
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

10.  On the primary structure of human plasminogen and plasmin. Purification and characterization of cyanogen-bromide fragments.

Authors:  B Wiman; P Wallén
Journal:  Eur J Biochem       Date:  1975-09-15
View more
  38 in total

Review 1.  The human plasma fibrinolytic system: regulation and control.

Authors:  K C Robbins
Journal:  Mol Cell Biochem       Date:  1978-08-16       Impact factor: 3.396

2.  Purification and reaction mechanisms of the primary inhibitor of plasmin from human plasma.

Authors:  U Christensen; I Clemmensen
Journal:  Biochem J       Date:  1978-11-01       Impact factor: 3.857

3.  Kinetic properties of the primary inhibitor of plasmin from human plasma.

Authors:  U Christensen; I Clemmensen
Journal:  Biochem J       Date:  1977-05-01       Impact factor: 3.857

4.  Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

Review 5.  α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.

Authors:  Guy L Reed; Aiilyan K Houng; Satish Singh; Dong Wang
Journal:  Semin Thromb Hemost       Date:  2016-07-29       Impact factor: 4.180

6.  Impact of the Pla protease substrate α2-antiplasmin on the progression of primary pneumonic plague.

Authors:  Justin L Eddy; Jay A Schroeder; Daniel L Zimbler; Lauren E Bellows; Wyndham W Lathem
Journal:  Infect Immun       Date:  2015-10-05       Impact factor: 3.441

7.  Reagents for reversible coupling of proteins to the active centres of trypsin-like serine proteinases.

Authors:  S B Kalindjian; R A Smith
Journal:  Biochem J       Date:  1987-12-01       Impact factor: 3.857

8.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

9.  Synthesis and secretion of alpha 2-plasmin inhibitor by established human liver cell lines.

Authors:  H Saito; L T Goodnough; B B Knowles; D P Aden
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

10.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.